Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Sintilimab |
Trade Name | |
Synonyms | IBI308|Tyvyt |
Drug Descriptions |
Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988). |
DrugClasses | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 |
CAS Registry Number | 2072873-06-2 |
NCIT ID | C132992 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anlotinib + Sintilimab | Anlotinib Sintilimab | 1 | 0 |
Bevacizumab + Sintilimab | Bevacizumab Sintilimab | 0 | 0 |
Cisplatin + Fluorouracil + Sintilimab | Cisplatin Fluorouracil Sintilimab | 0 | 1 |
Cisplatin + Paclitaxel + Sintilimab | Cisplatin Paclitaxel Sintilimab | 0 | 1 |
Fruquintinib + Sintilimab | Fruquintinib Sintilimab | 0 | 0 |
IBI110 + Sintilimab | IBI110 Sintilimab | 0 | 0 |
LY3537982 + Sintilimab | LY3537982 Sintilimab | 0 | 1 |
Nab-paclitaxel + Sintilimab | Nab-paclitaxel Sintilimab | 0 | 0 |
Sintilimab | Sintilimab | 0 | 4 |